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A BST R A C T 
 
  
            This project ?????????????????????????????????????????????????? subject of stem cells, 
and investigating how this technology affects society.  We will initially describe the different 
types of stem cells and how they are being used to benefit society.  The later chapters will 
investigate stem cell ethics and the laws regulating research funding in this area, domestically 
and internationally.  At the end, the authors provide their own conclusions on this complex but 
interesting technology. 
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PR OJE C T O BJE C T I V ES 
     
The purpose of this IQP is to investigate the technology of stem cells, and view the 
impact of this technology on society.  In Chapter-1 we discuss the different types of stem cells, 
where we obtain them from, their potential for differentiation, and the classifications under 
which they fall.  Chapter-2 describes the different types of medical applications stem cells have 
been used for, focusing on both animal experiments and human clinical trials. Chapter-2 also 
gives insight into which applications can be accomplished in the near future.  In Chapter-3 we 
take a different approach by looking into the ethics of stem cells from the point of view of the 
????? ??????????????????????. Chapter-4 looks at various domestic and international laws 
regulating stem cell funding.  Finally, the authors make their own conclusions based on their 
point of view of the subject, and discuss which stem cell laws the authors agree with best. 
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Chapter-1:  Stem Cell Types 
Ali Algarni 
 
Stem cells are long-lived cells that have the ability to differentiate into other kinds of 
tissues.  These cells have caused much excitement in the medical community due to their 
potential to replace wounded or diseased tissues in the body, and are the basis of the field of 
regenerative medicine.  But their use is also accompanied by much controversy, as the use of 
some types of stem cells destroys a living embryo.  However, not all stem cells are alike, and in 
fact most do not destroy an embryo.  The purpose of this chapter is to describe the main types of 
stem cells, and describe their potencies and origins.  The topic of stem cells is well suited for a 
WPI IQP project designed to investigate the impact of technology on society. 
 
Stem Cell Potencies 
Stem cells differ on the basis of their ability to differentiate into other tissues.  The more 
tissues a stem cell can form, the higher its potency.  Totipotent cells have the potential to form an 
entire organism plus extra-embryonic tissue (such as the placenta) (Brown University, 2002).  
Newly fertilized eggs through about the 8-cell stage are classified as totipotent.  As these cells 
continue to divide, they rapidly lose their totipotency, so these cells are not used for therapy. 
Pluripotent stem cells have the ability to form any cell in the organism, but not extra-
embryonic tissue.  These cells are taken from an embryo at about the 100-cell stage (blastocyst).  
The blastocyst consists of an outer layer of cells termed the trophoblast, and an inner cell mass 
(ICM) containing embryonic stem (ES) cells (Explore Stem Cells, 2012a; NIH Basics, 2012). 
Multipotent stem cells have the ability to differentiate into several types of related cells, 
but these cells cannot create all cells in the body (Explore Stem Cells, 2012b).  One example in 
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this category is a hematopoietic stem cell (HSCs) which can form all the various cellular 
components of blood, such as red blood cells, T-cells, B-cells, and platelets. However, HSCs do 
not normally form cells unrelated to blood (NIH Chapter-5, 2012).  Another example is a 
mesenchymal stem cell (MSC) that forms various kinds of mesodermal tissues, such as bone, fat, 
and muscle (Medwell Journals, 2011).  Neural stem cells (NSCs) can form glia and neural cells, 
but they are not capable of creating blood cells (NIH Chapter-8, 2012). 
Unipotent stem cells are derived from multipotent stem cells, and exist in adult tissues to 
??????????????????????????????????????????????????????????????????????????????????????????????????
differentiate, and usually replace only the tissue in which they are found.  One example in this 
category is a skin stem cell which is continuously dividing to replace dead or damaged skin cells 
(Alonso and Fuchs, 2003). 
 
Stem Cell Types 
Stem cells can also be classified on the basis of their origin.  Embryonic stem cells are 
obtained from embryos, parthenote stem cells are obtained from unfertilized eggs, and the 
remainder are obtained from adult tissues or umbilical cord blood. 
 
Embryonic Stem Cells 
Embryonic stem (ES) cells are derived from an embryo at about the 100-cell stage.  This 
type of stem cell is the most controversial because the embryo dies after the ES cells have been 
extracted.  In the U.S., these embryos are created by in vitro fertilization (IVF) for reproductive 
purposes. Extra embryos are created for couples for these reproductive purposes. However, this 
process is not efficient and there is no guarantee of success. It is not currently legal to fertilize 
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the embryos solely for research purposes. But once the family has enough children, with consent 
their extra embryos can be used for research purposes.  Human ES cells were first isolated and 
grown in 1998 (Thomson et al., 1998).  In this process, at an IVF clinic, donated sperm and egg 
are mixed together in a test tube, and left to culture for about four to five days until it reaches the 
blastocyst stage (about 100 cells). The blastocyst consists of an outer layer of cells, termed the 
trophoblast, and an inner cell mass composed of ES cells (F igure-1).  The inner cell mass is 
extracted from the embryo, and plated onto a feeder layer of cells that provide the right 
environment for the ES cells to divide.   
 
 
 
 
F igure-1: The Isolation of Human ES Cells.  This 
figure shows how embryonic stem cells are isolated and 
grown.  IVF embryos (diagram upper left) are grown to 
the blastocyst stage (middle diagram) from which the 
inner cell mass (blue) is isolated and plated onto a 
feeder layer of cells (lower diagram) for growth. 
(Thomson and Wu, 2006) 
 
 
 
 
 
 
ES cells are medically the most important type of stem cell due to their ability to form 
any cell in the adult organism (Explore Stem Cells, 2012a).  In animal experiments, the growth 
and differentiation of ES cells has allowed us to produce most tissues in the body.  Because the 
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embryo is usually killed while extracting ES cells, much research has focused on trying to avoid 
the embryo if possible, and on adult stem cell alternatives to ES cells for treating specific 
diseases.  One recent group claims to be able to create ES cell lines from single blastula cells 
without destroying the embryo (Klimanskayza et al., 2006).  And in 2005, the same group at 
Advanced Cell Technology created ES cell lines without using any feeder layer, which lowers 
the risk of possible viral contaminants (Klimanskayza et al., 2005). 
 
Hematopoietic Stem Cells 
Hematopoietic stem cells (HSCs) are responsible for creating all the cellular components 
of blood, including red blood cells, white blood cells (T-cells, B-cells, neutrophils, 
macrophages), and platelets (NIH Chapter-5, 2012). Scientists first speculated on the existence 
of HSCs in 1956 when it was shown that bone marrow has the ability to reconstitute the blood in 
mice following radiation treatment (Ford et al., 1956).  Since then, HSCs have been used for over 
50 years in bone marrow transplants for treating various cancers of the blood (like leukemia or 
lymphomas) following chemotherapy or radiation treatments (Thomas et al., 1957).  HSCs are 
usually obtained from bone marrow, where they reside to help replace blood cells in the body.  
??????????????????????????????????????????????????????????????????????????????????????????????????
marrow can be painful, so scientists have researched procedures for obtaining HSCs elsewhere.   
One alternative procedure for obtaining HSCs isolates them from the peripheral blood of 
a donor after injection with hormones to induce the migration of HSCs from the marrow into the 
periphery.  Although the HSCs represent only a small percentage of cells in the peripheral blood, 
they can be concentrated by selecting them on the basis of cell surface markers, such as CD-34+ 
(Spangrude et al., 1988).  Another alternative source of HSCs is umbilical cord blood, which is 
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very rich in these cells.  Umbilical cord blood is donated at time of birth, and frozen in case the 
child develops problems later in life.  HSCs obtained from cord blood are more primitive than 
those isolated from bone marrow, so they are less likely to be rejected by the patient (Viacord, 
2011). 
Researchers have also discovered that HSCs may be able to form cells other than blood, 
such as blood vessels, bones, and muscle tissues. This property is termed plasticity. These 
observations have only been made in animals, but if plasticity is found in human HSCs it might 
mean HSCs could be used to create a wider variety of tissues than originally thought.  This could 
provide for the replacement of organs such as the liver or heart without using ES cells.  
However, not all scientists believe in this plasticity, so more research is needed to show that it 
actually exists. 
 
Neural Stem Cells 
Previously, many scientists thought that once brain cells got damaged they could never be 
replaced. Most of our current treatments for brain or spinal cord injuries attempt to stabilize the 
?????????? ?????????????????????????????????????????????????????????????????????????????????
areas of the brain contain adult brain cells with the ability to give rise to new neurons and their 
??????????????????????????????????????????????????????? were first isolated from rat brains in 1989 
(Temple, 1989), and in 1993 neural stem cells were first isolated from the ependymal zone of 
mouse brains (Morshead et al., 1993).  It was observed that some areas of the brain can produce 
new neurons which rise from neural stem cells. NSCs are very similar to the cells of the 
developing fetus that first give rise to the brain and the spinal cord.  The research eventually 
showed that NSCs can give rise to all cell types in the adult brain, which raises the hope of 
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someday being able to repair damage from neuro-???????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????-8, 2012). 
 
Mesenchymal Stem Cells 
MSCs are multi-potent stem cells isolated from bone marrow periosteum and muscle 
connective tissue. They have the ability to differentiate into many kinds of mesodermal lineages, 
including bone, fat, muscle, and cartilage (Pittenger et al., 1999; Medwell Journals, 2011).  
MSCs are usually isolated from bone marrow due to the relative ease of extraction.  MSCs were 
the second type of stem cell discovered (after HSCs), and resulted from research in Russia by 
Friedenstein on muscle-generating cells (Friedenstein, 1976).  Due to their multi-potency, 
relative ease of isolation, and lack of embryo destruction, MSCs have become one of the most 
popular cells to research.  One of their many potential applications is bone formation where they 
are used to help fill in bone fractures or to restore bone to its original state. 
 
Cardiac Stem Cells 
Just as scientists originally thought that brain cells were incapable of regeneration, they 
also thought that heart cells could not regenerate.  But recent studies have found that c-kit 
positive cells located in rat heart muscle can help replace cardiomyocytes, so these cardiac stem 
cells (CSCs) might be suitable for heart therapy (Beltrami et al., 2003).  At the Heart Institute of 
Japan, scientists isolated c-kit (+) cells, placing them in culture (Miyamoto et al., 2010).  The 
cells showed cardiosphere generation and the potential to differentiate into three main lineages: 
cardiomyocytes, smooth muscle, and endothelial cells in vitro (Miyamoto et al., 2010). Over 
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long term culture, the cells were also able to differentiate into cells other than cardiac lineages, 
such as adipocytes and skeletal myocytes.  
However, some scientists believe the c-kit+ cells are not true CSCs and are merely HSCs 
that have migrated to the heart from the blood.  In 2005, another group of scientists isolated Isl1+ 
cells from mouse, rat, and human hearts, and they believe these cells represent true CSCs 
(Laugwitz et al., 2005).   
 
Adult Eye Stem Cells 
Our own eyes have recently been shown to contain nerve stem cells (Salero et al., 2012). 
New research has revealed that a single layer of cells at the back of the eye, termed the retinal 
pigment epithelium (RPE), contains cells that help replace photoreceptors.  Hopefully, the use of 
these cells can help patients with some types of vision loss.  However, these new cells have not 
been fully tested for their differentiation capacity.  
 
Adult Lung Stem Cells 
A new discovery has revealed that stem cells reside in the lungs, and are able to 
differentiate to a variety of cell types (The Huffington Post, 2012). The cells were taken from a 
human lung and injected into a mouse to allow engraftment and differentiation.  The cells 
successfully formed lung airways, air sacs, and blood vessels. Although we need more research 
into this type of stem cells, many scientists believe that the finding may help treat certain types 
of lung diseases. 
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Skin Epithelial Stem Cells 
Mammalian skin was first shown to have cells capable of replenishing skin in 1981 
(Bickenback, 1981).  This type of cell supplies the skin with its replacement cells and can be 
used to generate new skin for burn patients.  But skin stem cells are still not easily 
distinguishable from cells surrounding them.  Recently scientists have made attempts to 
characterize these cells more fully in mice and humans (Bach et al., 2000). Some of the cells 
exhibited prodigious proliferative potential, and were adapted for treating burn patients in one of 
the first applications for stem cells (apart from bone marrow transplants). 
 
Renal Stem Cells 
Kidney stem cells may also exist, especially in the epithelial ureteric bud cells. If these 
cells help replace kidney epithelium, perhaps they could be used to help generate tubules in 
kidney patients.  However, there is not much research about this type of cell.  
 
Adult Intestinal Stem Cells 
Intestinal stem cells are found at the base of intestinal crypts (Bach et al., 2000), and are 
always undergoing the process of altruistic apoptosis because they are exposed to toxic stimuli.  
Intestinal epithelial cells turn-over at a very high rate due to the grinding forces associated with 
food movement and digestion.  Arguments exist between scientists about whether the mature 
intestinal cells derived from the crypt derive from either single or multiple stems.  Research has 
also focused on determining the potential role of these cells in colorectal tumors, and whether 
tumors originate from single mutated intestinal stem cells (NIH Chapter-3, 2012). 
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Parthenogenic Stem Cells 
Parthenogensis is a mode of asexual reproduction in which embryonic development can 
begin without any sort of sperm or male participation. This is a common way of reproduction in 
some insects and lower organisms, such as ants, lizards, snakes, and crayfish.  Mammalian 
parthenogenesis does not exist in nature, but can be artificially induced.  Monkey parthenote 
embryos were first created in 2001 (Mitalipov et al., 2001).  The parthenogenesis was initiated 
using chemicals such as strontium chloride or electrical current, and the unfertilized egg began 
dividing without extruding one set of chromosomes as it normally does during egg development. 
Thus, the egg remained diploid.  The parthenote embryo divided through the blastocyst stage 
from which ES cells could be isolated, but the embryo did not survive much longer.  Further 
experiments on monkey parthenote embryos were performed in 2002 by scientists at Advanced 
Cell Technology (ACT) (Cibelli et al., 2002). They tricked 77 monkey eggs by chemicals to 
believe that they had been fertilized.  Twenty-eight embryos started dividing, and four reached 
the blastocyst stage during which ES cells were extracted and cultured into an ES cell line.   
??????????????????????????????????????? ??????????????? ??????????????????????????????
parthenote embryos (Cibelli et al., 2001).  But all their parthenote embryos never reached the 
blastocyst stage, so as a result no ES cell lines were derived.  In 2007, Brevini and Gandolfi also 
claimed to have made human parthenote ES cell lines (Brevini and Gandolfi, 2007), but this 
finding has not yet been verified.  If human parthenote ES cell lines can be derived, some 
scientists claim these cells would have fewer ethical concerns than fertilized embryos.  This topic 
will be discussed in more detail in Chapter-3. 
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Induced Pluripotent Stem Cells 
For the past few years, the stem cell world has been excited by a new type of stem cell 
called the induced pluripotent stem (iPS) cell (Baker, 2007). This new type of stem cell may be 
virtually as potent as an ES cell, but would not destroy an embryo to derive them.  And equally 
importantly, they would be genetically identical to the patient used to derive them, so would be 
less likely to be rejected.  If iPS cells were shown to be as potent as ES cells, they could be used 
to create any type of cell in the body.  These cells were first derived from mouse skin fibroblast 
cells in 2006 (Takahashi and Yamanaka, 2006), and one year later were derived from human 
skin fibroblast cells (Takahashi et al., 2007).  In these initial experiments in Japan, skin fibroblast 
cells were reprogrammed from a differentiated state to an undifferentiated state by introducing 
genes encoding four transcription factors: OCT3/4, SOX2, KLF4, and c-Myc. The cells could be 
expanded into more iPS cells, or they could be differentiated.   
The level of iPS cell potency is controversial.  Some scientists claim iPS cells are as 
potent as ES cells derived from fertilized embryos.  Their doubling time is about the same, and 
the types of tissues formed are about the same as well.  The activity of the enzyme telomerase, 
which helps maintain the ends of chromosomes during long periods of cell division, was also 
about the same between the two cell types.  And their overall gene expression patterns appeared 
to be about the same.  However, other scientists have shown that iPS cells have mutations in 
their DNA (Gore et al., 2011), so they may not be as potent as ES cells (Hayden, 2011). 
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Chapter-2: Stem Cell Applications 
Abdulla Al-Abri 
 
In spite of great advances in medical research over the past century, human illnesses 
continue to deprive people of health, independence, and well-being (Chapman, 1999).  Scientists 
are continually seeking new remedies for human diseases. Recently, advances in science, 
medicine, and technology have created a new field of medicine termed regenerative medicine 
that is based on the ability of stem cells to regenerate tissues.  As discussed in the previous 
chapter, stem cells are unspecialized cells capable of renewing themselves through cell division.  
They may replicate many times creating new stem cells, or they can become induced to 
differentiate into tissue-specific or organ-specific cells with specialized functions.  In some 
organs, such as the gut and bone marrow, stem cells regularly divide to repair and replace worn 
out or damaged tissues on a small scale, so the idea of regenerative medicine is to use these 
properties to repair damaged tissues on a larger scale to treat organs damaged by diseases.   
 As discussed in Chapter-1, stem cells are of two main types: embryonic stem (ES) cells 
and adult or somatic stem cells.  ES cells can be used to create cell lines for producing large 
numbers of cells for therapy, and are pluripotent, so they can create any type of tissue in the adult 
organism (Hughes, 2005).  Because ES cells are derived from 5-day old blastocyst embryos (Yu 
and Thomson, 2006), and their derivation destroys the embryo, ES cells are ethically 
controversial.  Adult stem cells are isolated from adult tissues, and have fewer ethical issues.  
Medically, ES cells and adult stem cells are not equal.  ES cells can relatively easily be grown to 
large cell numbers in vitro and are pluripotent, while adult stem cells are rare in adult tissues, are 
hard to isolate and purify, are hard to grow, and usually can create relatively few types of tissue. 
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 The ability of stem cells to treat diseases, or their potential to do so, represents their 
benefits to society, which strongly factor into their ethics.  The purpose of this chapter is to 
describe how stem cells have been used, or potentially will be used, to treat six specific example 
diseases.  Special attention will be paid to whether the treatments are well proven or are only in 
experimental stages, as this relates strongly to their ethics. 
 
Hematopoietic Stem Cell Applications 
The hematopoietic system refers to the blood forming system of the body (Weissman et 
al., 2001).  The cells that produce all the cellular components of blood are termed hematopoietic 
stem cells (HSCs).  These cells are multi-potent, with the ability to form several types of related 
cells, such as red blood cells, white blood cells (T-cells, B-cells, neutrophils, macrophages), and 
platelets.  But HSCs are not pluripotent, and usually do not form cells unrelated to blood. 
Bone marrow is the traditional source of HSCs, and these cells have been researched for 
over 50 years, representing the best characterized of all the stem cell types.  Some of the best 
success stories for stem cells come from the treatment of blood cancers (leukemia and 
lymphoma) with HSCs, with cure rates as high as 98% for some types of cancer (Abbott, 2003; 
Gluckman, 2009; Gratwohl et al., 2010).  During blood cancer ???????????????????????????????????
marrow cells are destroyed by chemotherapy or radiation, and then they are replaced by a bone 
marrow transplant, either from their own bone marrow or a histo-compatible donor.  The first 
successful bone marrow transplants for leukemia were performed in 1957 using identical twin 
donors (Thomas et al., 1957).   Since then, other more convenient sources of HSCs have been 
??????????????????????????????????????????????????????????????????????????????????????????????
following the injection of hormones that stimulate the movement of HSCs from the marrow to 
 20 
the blood, and the use of umbilical cord blood (Viacord, 2011).  By 1995, more than 40,000 
transplants were performed annually worldwide (Panchision, 2006). 
Embryonic stem cells also provide a potential future source of HSCs. Both mouse and 
human ES cells have yielded HSCs in vitro, and they do so relatively readily (Weissman et al., 
2001). However, recognizing actual HSCs in those cultures has proven problematic, which may 
reflect the difficulty in identifying HSC markers.  CD34 was the first cell surface marker 
??????????? ???? ????? ??? ?????????????????? ???? ??????????? ??? ????? ??????? ???? ?????? ????? ??????
newer markers have also been identified, and ES cells have been shown to also create these cells.  
However, using ES cells for therapy remains only a theoretical possibility for now because of 
host-recipient compatibility problems, and due to ES cell ethical issues. 
 
Stem Cell T reatment of Diabetes 
 In people who suffer from Type-I diabetes, the cells of the pancreas that normally 
???????? ????????????????????????? ????????????????????????????????? ? ???????? ????????????? ?????
increases the uptake of blood glucose into tissues, so in its absence, serum glucose increases.  
Although pancreatic tissue transplants have been performed in diabetic patients, one of the major 
challenges is an insufficient supply of histo-compatible tissue (Goldthwaite, 2006). 
New studies indicate that it may be possible to treat diabetes using stem cells, either adult 
pancreatic stem cells, or ES cells differentiated into insulin-secreting cells.  Animal studies show 
that mouse ES cells can be differentiated in vitro to insulin-producing cells, and these cells 
restore normal glycemia in a mouse diabetes model (Soria et al., 2000).  Mouse diabetic models 
have also been successfully treated with induced pluripotent stem (iPS) cells derived from mouse 
skin cells (Alipio et al., 2010). This iPS cell approach has scientists excited, because the 
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therapeutic cells can be prepared from a skin cell of the same diabetic patient they are to be 
transplanted back into, and the process does not destroy an embryo, unlike ES cells.  Mouse 
diabetic models have also been successfully treated with human ES cells that differentiated in 
vivo into insulin-producing cells (Kroon et al., 2008). 
 Treatment of human diabetes patients with stem cells has not yet been performed.  
However, several studies have shown that human ES cells are capable of differentiating into 
insulin-producing cells (Assady et al., 2001; Lumelsky et al., 2001; Seguev et al., 2004; 
??????????????? Current efforts to treat diabetic patients with human islet transplants to restore 
insulin secretory function are limited severely by the small numbers of donated pancreas 
available each year, combined with the toxicity of immunosuppressive drug treatments required 
to prevent graft rejection (Chapman, 1999).  
 
Stem Cell T reatment of Damaged Heart Muscle 
 Cardiovascular diseases can deprive heart tissue of oxygen, thereby killing cardiac 
muscle cells.  This loss can result in the formation of scar tissue, overstretch the remaining 
cardiac cells, and decrease cardiac output.  Because donated hearts are always in short supply, 
restoring damaged heart muscle tissue through regeneration is a potentially new strategy to treat 
heart failure (Goldthwaite, 2006). 
 The treatment of human heart attack patients with stem cells is the second most advanced 
area of stem cell applications (following the HSC treatment of leukemia).  Usually these 
procedures are performed in patients who are already undergoing open-heart surgery, and 
involve either injecting the cells into the circulation or directly into the injured heart tissue.  The 
exact mechanism of repair remains somewhat controversial, but the stem cells likely regenerate 
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heart tissue through several cardiac-specific pathways (Goldthwaite, 2007).  Human heart attack 
patients were first treated with skeletal myoblast cells in 2001 (Menasche et al., 2001; Siminiak 
et al., 2004), and were later treated with bone marrow stem cells (Britten et al., 2003; Lunde et 
al., 2006; Schächinger et al., 2006), then mesenchymal stem cells (Chen et al., 2004), and finally 
adult cardiac stem cells (GEN, 2011).  Menasche (2002) summarizes the results of several phase-
I clinical trials using skeletal myoblast transplants to treat human heart ailments.  One phase-I 
study using autologous skeletal myoblast transplantation was initiated on June 15, 2000, and has 
already been completed with 10 patients.  The phase-I trial established the general feasibility of 
the myoblast procedure, and demonstrated the ability to reach a specified number of target cells 
within a pre-set time frame of 2 to 3 weeks.  The operation by itself was shown to be safe 
without specific procedure-related complications.  The only adverse event was ventricular 
tachycardia, which occurred in 4 patients.  It has suggested that the incidence and severity of the 
arrhythmias could be reduced by an appropriate prophylaxis using the drug amiodarone. Other 
phase-I studies were also done, and support the feasibility and safety of the myoblast procedure.  
Heart attack patients have not yet been treated with embryonic stem cells, but human ES 
cells have been shown to be able to differentiate into various cardiac lineages (Kehat et al., 
2001). 
 
?????????????????????????????????????????? 
Intensive research aimed at curing Parkinson's disease (PD) with stem cells is a good 
example of the various strategies, successful results, and remaining challenges of stem cell-based 
brain repair. PD is a progressive neurological disorder of motor control that affects roughly 2% 
of persons 65 years and older. PD often begins with minor muscle tremors that eventually 
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progress to limb and bodily rigidity, and difficulty initiating movement. PD is triggered by the 
???????????????????????????????????????????????substantia nigra??????????????????????????????????
axons to another region called the striatum, composed of subregions called the caudate nucleus 
and the putamen. The substantia neurons release the chemical transmitter dopamine onto their 
target neurons in the striatum. One of dopamine's major roles is to regulate body movement. As 
these dopaminergic cells die, less dopamine is produced, leading to the movement difficulties. 
Currently, the causes of death of the substantia neurons are not well understood (Pachision, 
2006). 
For many years, doctors have treated PD patients with the drug levodopa (L-dopa), a 
chemical precursor to dopamine, which the brain readily converts into dopamine. Although the 
drug initially works well, levodopa eventually loses its effectiveness, and side-effects increase. 
Ultimately, many doctors and patients find themselves fighting a losing battle. For this reason, a 
huge effort is underway to develop new treatments (Pachision, 2006). 
With respect to cell therapy, human PD patients were initially treated with fetal tissue 
transplants isolated from aborted fetuses (Madrazo et al., 1988; Lindvall et al., 1989; Freed et al., 
2001, Mendez et al., 2002). Although this technique had some success, the use of aborted tissue 
in medical research was too ethically controversial, so this technique is no longer used.  Human 
PD patients have also been treated with adult olfactory mucosal stem cells (Levesque, 2005), and 
with adult neuronal stem cells (Ertelt, 2009).  The latter technique appears to hold some promise, 
as no tumors formed at the injection site. Using adult NSCs to treat PD may hold promise, based 
on related work treating stroke patients with similar cells (Arvidsson, et al., 2002).  That 
pioneering study on neuronal replacement using adult neural stem cells after stroke was the first 
to comprehensively show that new neurons have the capability to replace cells lost at the site of 
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an insult.  The experiments confirmed that the increase in newly born cells at the ipsilateral 
striatum (ST) was a result of increased cell proliferation and recruitment of neuroblasts.  
However, the apparent regeneration of new neurons only accounted for 0.2 % of the lost striatal 
neurons in the stroke (Arvidsson et al., 2002). 
Embryonic stem cells have had some success in PD animal models, but have not yet been 
used to treat human patients, although human ES cells have been shown to be capable of 
differentiating into dopamine-producing neurons (Perrier et al., 2004). These ES cells were 
shown to have differentiated into both dopamine and serotonin neurons.  This latter type of 
neuron is generated in an adjacent region of the brain and may complicate the response to 
transplantation in PD patients. Since ES cells can generate all cell types in the body, unwanted 
cell types such as muscle or bone could theoretically also be introduced into the brain, although 
hopefully the injection environment will prevent this from happening. As a result, a great deal of 
effort is being currently put into finding the right way to turn ES cells only into dopamine 
neurons (Pachision, 2006). 
One method with great therapeutic potential is somatic cell nuclear transfer (SCNT). This 
method fuses the genetic material from the nucleus of a skin fibroblast (somatic) cell of a donor 
with a recipient egg cell that has had its nucleus removed. If the resulting early embryo can 
survive for 5 days to the blastocyst stage, ES cells can be derived from the inner cell mass.  
These ES cells would be genetically identical to the donor of the skin cell, so in theory this 
technique could be used to make ES cells that are compatible with a human patient.  This process 
???????????????????????????????????????????????????????????by some to be ethically questionable. 
SCNT was first performed in sheep in 1996 (Campbell et al., 1996).  Human SCNT was claimed 
in 2007, but was later proven to be a hoax (Hwang et al., 2007).  Mouse ES cells have been 
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derived successfully in this way, and were differentiated into dopamine neurons that corrected 
Parkinsonian symptoms when transplanted into 6-OHDA-treated rats (Garfinkel, 2005). ES cell 
lines have also been derived from parthenote embryos created by stimulating unfertilized eggs 
with chemicals or electric current to stimulate egg division without loss of one set of 
chromosomes.  These alternative approaches may eventually offer the possibility of treating 
patients with genetically matched cells, thereby eliminating the possibility of graft rejection 
(Garfinkel, 2005), but have not yet been achieved with human embryos. 
Scientists are also studying the possibility that the brain may be able to repair itself with 
therapeutic support. This approach is in its early stages, but may involve administering drugs that 
stimulate the formation of new neurons from the brain's own stem cells. The approach is based 
on research showing that new nerve cells are born in the adult brains of humans in a brain region 
called the dentate gyrus of the hippocampus (Panchision, 2006). While it is not yet clear how 
these new neurons contribute to normal brain function, their presence suggests that stem cells in 
the adult brain may have the potential to re-wire dysfunctional neuronal circuitry. 
 
Stem Cells T reatment of Strokes 
Stroke affects about 750,000 patients per year in the U.S. and is the most common cause 
of disability in adults. A stroke occurs when blood flow to the brain is disrupted. As a 
consequence, cells in the affected brain regions die from insufficient oxygen. The treatment of 
stroke with anti-clotting drugs has dramatically improved the odds of patient recovery. However, 
in many patients the damage cannot be prevented, and the patient may permanently lose body 
functions.  
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For stroke patients, researchers are now considering the use of stem cells as a way to 
repair the damaged brain regions. This problem is challenging because stroke damage may be 
widespread and may affect many cell types and connections (Panchision, 2006). Human stroke 
patients have been treated with mesenchymal stem cells (Bang et al., 2005) and with HSCs 
???????????? ??? ????? ??????? ??? ????????? ?????? ?????????? ???????? ????????????? ?? ?????????? ????
bone marrow stem cells into a 54 year old woman who had a stroke.  She had lost movement on 
the right side of her body and could not understand other people or communicate with them.  17 
days after the transplant she was discharged from hospital, having recovered movement, 
comprehension and some speech, and further improvements were reported in the following 
months (Khalip, 2004). 
Newer experiments have focused on treating stroke patients with mesenchymal stem cells 
(MSCs).  MSCs, like other stem cells, have the capacity of unlimited self-renewal giving rise to 
differentiated cells from various cell lineages.  Bone marrow (BM)-derived MSCs are the most 
frequently used MSC type in experimental stroke studies.  Application of BM-derived MSCs 
and, in some studies, transplantation of MSCs from other tissue sources resulted in an improved 
functional recovery in experimental animals, although stroke volumes were not always improved 
by the MSC transplantation (Doeppner, et al., 2010).   
Taking an alternative approach, another research group attempted a cell transplantation 
supplemented with a scaffold as a means to treat the loss of brain mass after a severe stroke. By 
adding stem cells onto a polymer scaffold that they implanted into the stroke-damaged brains of 
mouse, the researchers demonstrated that the seeded stem cells differentiated into neurons while 
the polymer scaffold reduced scarring (Park et al., 2002). Two groups transplanted human fetal 
stem cells in independent studies into the brains of stroke-affected rodents; these transplanted 
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stem cells not only survived but migrated to the damaged areas of the brain. These studies 
increase our knowledge of how stem cells are attracted to diseased areas of the brain (Panchision, 
2006). 
Researchers from Sweden recently observed that strokes in rats cause the brain's own 
stem cells to divide and give rise to new neurons (Arvidsson et al., 2002).  However, these 
neurons, which survived only two weeks, are too few in number compared to the damaged area. 
A research group from the University of Tokyo added a growth factor, bFGF, into the brains of 
rats after stroke, and showed that the hippocampus was able to generate large numbers of new 
neurons, and the new neurons were actually making connections with other neurons (Nakatomi 
et al., 2002). These and other results suggest that future stroke treatments may be able to coax the 
brain's own stem cells to make replacement neurons (Panchision, 2006). 
 
Stem Cell T reatment of Scleroderma 
Scleroderma is an autoimmune disease that affects connective tissue in the body, the 
tissue that supports skin and internal organs.  This disease causes organs to grow hard and thick.  
Amy Daniels is a successfully treated patient of Dr. Burt on this disease (Stem Cell Research, 
2008).  Her scleroderma caused her skin to become very tight, she could not bend her head 
backwards, and she could not make a fist or cross her fingers.  Her teeth were getting loose, and 
she had trouble closing her mouth.  Her illness got worse as it attacked her lungs, decreasing 
their capacity from over 90 percent to 43 percent.  She was given chemotherapy and 
immunosuppressant to eliminate her malfunctioning immune system.  In April 2007, her own 
adult stem cells were re-infused to her body to rebuild her immune system.  After 6 months, she 
returned to work, her skin returned to normal, and her lung capacity increased to 57 percent 
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(Saunders, 2008).  Although this is only one case, it provides hope for others affected by 
scleroderma. 
 
General Applications 
Human stem cells have also been found to be beneficial in treating other serious medical 
conditions like cancer and birth defects.  Human stem cells isolated from patients can also be 
used as disease models to test drugs.  New medications could be tested for safety on 
differentiated cells generated from human pluripotent cell lines (Weissman, 2001).   
 
Chapter-2 Conclusions 
The most important potential application of human stem cells is the generation of cells 
and tissues for cell-based therapies.  Stem cells, directed to differentiate into specific cell types, 
offer the possibility of a renewable source of replacement cells to treat diseases (Weissman, 
2001). To realize the promise of cell-based therapies for such pervasive and debilitating diseases, 
scientists are challenged to be able to manipulate stem cells so that they possess the necessary 
characteristics for successful differentiation and transplantation.  
Human embryonic stem cells have the potential to provide an unlimited amount of tissue 
for transplantation therapies to treat a wide range of degenerative diseases.  These useful cells 
can be grown into cell lines for producing large numbers of cells for therapies.  However, there 
are a number of challenges associated with ES cell therapies, including histo-compatible 
matches, the occasional formation of tumors at the injection site, and ethical issues.  So, many 
years of basic research will be required before ES cell therapies can be used to treat patients 
(Panchision, 2006). 
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 It has been 14 years since the initial derivation of human embryonic cells in 1998 
(Thomson et al., 1998).  As of 2006, more than 120 human ES cell lines have been established, 
and 67 of them are included in the National Institutes of Health Registry (Panchision, 2006).  
Twenty-one cell lines are currently available for distribution.  Unfortunately, all of these ES cell 
lines have been exposed to animal products during their derivation, as they were cultured with 
mouse fibroblast feeder layer cells (Panchision, 2006). However, scientists have now devised a 
procedure for deriving ES cells without using any feeder cells (Klimanskayaet al., 2005). 
 Most of the research studies performed so far have shown that using adult stem cells to 
treat blood cancers is the most characterized of all the stem cell treatments, and that the 
treatments the closest to expanding to wide spread use in human patients are treating heart 
attacks and strokes with adult stem cells.  However, experiments with animal models have led 
the way in most cases, and will continue to provide more opportunities to treat human diseases in 
the future. 
 
Chapter-2 Bibliography 
 
Abbott, Cate (2003) Bone Marrow Transplantation.  London Health Sciences Centre. 
http://www.lhsc.on.ca/transplant/bnmarrow.htm.  
 
Alipio Z, Liao W, Roemer EJ, Waner M, Fink LM, Ward DC, Ma Y (2010) Reversal of 
hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived 
????????????-like cells. Proceedings of the National Academy of Sciences, 107: 13426-13431.   
 
Amy Daniels (2008) Testimony on Capitol Hill Briefing in Washington DC on March 13, 2008. 
 http://stemcellresearch.org/testimony/20080313_daniels.html 
 
Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O (2002) Neuronal replacement from 
endogenous precursors in the adult brain after stroke.  Nature Medicine, 8: 963-970. 
 
Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki K, and Tzukerman M (2001) Insulin 
Production by Human Embryonic Stem Cells. Diabetes, 50: 1691-1697.   
http://diabetes.diabetesjournals.org/cgi/content/full/50/8/1691 
 30 
 
Bang OY, Lee JS, Lee PH, and Lee G (2005) Autologous mesenchymal stem cell transplantation 
in stroke patients.  Annals of Neurology, 57(6): 874?882.   
 
Britten MB, Abolmaali ND, Assmus B, Lehmann R, Honold J, Schmitt J, Vogl TJ, Martin H, 
Schächinger V, Dimmeler S, Zeiher AM (2003) Infarct Remodeling After Intracoronary 
Progenitor Cell Treatment in Patients With Acute Myocardial Infarction.  Circulation, 108: 
2212-2218. 
 
Campbell KH, McWhir J, Ritchie WA, Wilmut I (1996) Sheep Cloned by Nuclear Transfer 
From a Cultured Cell Line.  Nature, 380: 64-66.   
 
Chapman A (1999) Stem Cell Research and Applications. Retrieved from: 
http://www.aaas.org/spp/sfrl/projects/stem/report.pdf 
 
Chen S-I, Fang W-W, Ye F, et al. (2004) Effect on left ventricular function of intracoronary 
transplantation of autologous bone marrow mesenchymal stem cells in patients with acute 
myocardial infarction. American Journal of Cardiology, 94: 92-95.   
 
???????????????????????????????????????????????????expressing endocrine cells from human 
embryonic stem cells.  Nature Biotechnology, 24: 1392-1401.   
 
Doeppner TR, Hermann DM (2010) Mesenchymal stem cells in the treatment of ischemic stroke: 
progress and possibilities.  Dove Press Journal.  November 11, 2010. 
 
???????? ??????? ??????? ?????? ????? ????? ????????? ????????? ???????? ??? ???????????? ???????? ???
Human Trial.  LifeNews.com, February 16, 2009.   http://www.lifenews.com/bio2751.html 
 
Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, 
Culver S, Trojanowski JQ, Eidelberg D, and Fahn S (2001) Transplantation of embryonic 
dopamine neurons for severe Parkinson's disease.  New England Journal of Medicine, 344: 710-
719.   
 
?????????? ?? ??????? ????? ?????? ???? ???????????? ????????? International Society for Stem Cell 
Research.  Retrieved from: http://www.isscr.org/public/parkinsons.htm 
 
GEN (2011) First Clinical Trial of Autologous Cardiac Stem Cells Shows Positive Results.  
Genetic Engineering and Biotechnology News, Issue Nov 14, 2011. 
http://www.genengnews.com/gen-news-highlights/first-clinical-trial-of-autologous-cardiac-stem-
cells-shows-positive-results/81245949/ 
 
Gluckman E (2009) History of cord blood transplantation.  Bone Marrow Transplant,  
44: 621-626.   
 
Goldwaithe CA (2006) NIH Stem Cell Information, Chapter-7.  Are Stem Cells the Next Frontier 
for Diabetes Treatment? Retrieved from:  
http://stemcells.nih.gov/info/Regenerative_Medicine/2006Chapter7.htm 
 31 
 
Hughes BR (2005) Real-World Successes of Adult Stem Cell Treatments.  Family Research 
Council.  Retrieved from:  http://www.frc.org/index.cfm?i=IS04J01&f=WU04K19&t=e 
 
Hwang WS, Roh SI, Lee BC, Kang SK, Kwon DK, Kim S, Kim SJ, Park SW, Kwon HS, Lee 
CK, Lee JB, Kim JM, Ahn C, Paek SH, Chang SS, Koo JJ, Yoon HS, Hwang JH, Hwang YY, 
Park YS, Oh SK, Kim HS, Park JH, Moon SY, Schatten G (2005) Patient-specific embryonic 
stem cells derived from human SCNT blastocysts.  Science, 308: 1777-1783.   
 
Khalip A (2004) Brazilians to widen stem cell study in strokes.  Reuters 19 November 2004.  
Retrieved from http://www.spuc.org.uk/about/no-less-human/ethicalstemcells.pdf 
 
Klimanskaya I, Chung Y, Meisner L, Johnson J, West MD, Lanza R (2005) Human Embryonic 
Stem Cells Derived Without Feeder Cells. Lancet, 365(9471): 1636-1641.   
 
Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, et al. (2008) Pancreatic 
endoderm derived from human embryonic stem cells generates glucose-responsive insulin-
secreting cells in vivo.  Nature Biotechnology, 26: 443-452.   
 
LevesqueMF (2005) Senate Committee Testimony: Spinal Cord Injured Recipient of Adult Stem 
Cell Therapy.  http://www.leaderu.com/science/stemcelltestimony_levesque.html 
 
Lindvall O, Rehncrona S, Brundin P, et al. (1989) Human fetal dopamine neurons grafted into 
????????????????????????????????????????????????????????????????????????????????????????????????
and a 6-month follow-up.  Archives of Neurology, 46: 615-631.   
 
Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, and McKay R (2001) Differentiation of 
Embryonic Stem Cells to Insulin-Secreting Structures Similar to Pancreatic Islets.  Science, 292: 
1389-1394.    
 
Lunde K, Solheim S, Aakhus S, Arnesen H, et al (2006) Intracoronary Injection of Mononuclear 
Bone Marrow Cells in Acute Myocardial Infarction. The New England Journal of Medicine, 355: 
1199-1209.   
 
Madrazo I, Leon V, Torres C, et al. (1988) Transplantation of fetal substantia nigra and adrenal 
medu??????????????????????????????????????????????????????????????????????New England Journal 
of Medicine, 318: 51.   
 
Menasche, Philippe (2002)  Cell Transplantation in Myocardium.  Department of Cardiovascular 
Surgery. Paris, France. Retrieved from: 
http://ats.ctsnetjournals.org/cgi/content/full/75/6_suppl/S20#BIB34 
 
Menasche P, Hagege AA, Vilquin J-T, et al. (2003) Autologous skeletal myoblast transplantation 
for severe postinfarction left ventricular dysfunction.  J Am Coll Cardiol. 41: 1078-1083. 
 
Mendez I, Dagher A, Hong M, et al. (2002) Simultaneous intrastriatal and intranigral fetal 
dopaminergic grafts in patients with Parkinson disease: a pilot study.  Report of three cases. 
 32 
Journal of Neurosurgery, 96: 589-596.   
 
Nakatomi H, Kuriu T, Okabe S, et al. (2002) Regeneration of hippocampal pyramidal neurons 
after ischemic brain injury by recruitment of endogenous neural progenitors. Cell, 110: 429-441. 
 
Olanow CW, Goetz CG, Kordower JH, et al. (2003) A double-blind controlled trial of bilateral 
??????????????????????????????????????????????????????Annals of Neurology, 54: 403-414. 
 
Panchision DM (2006) Repairing the Nervous System with Stem Cells. Regenerative Medicine. 
Department of Health and Human Services.  
http://stemcells.nih.gov/staticresources/info/scireport/PDFs/E.%20Chapter%203.pdf 
 
Park KI, Teng YD, Synder EY (2002) The injured brain interacts reciprocally with neural stem 
cells supported by scaffolds to reconstitute lost tissue. Nature Biotechnology, 20: 1111?1117. 
 
Perrier AL, Tabar V, Barberi T, et al. (2004) Derivation of midbrain dopamine neurons from 
human embryonic stem cells.  Proc Natl Acad Sci USA, 101: 12543-12548.   
 
Saunders WJ, et al. (2008) Adult Stem Cell Success Stories.  Family Research Council. 
Retrieved from:  http://www.frc.org/insight/adult-stem-cell-sucess-stories-2008-jan-june 
 
Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, et al. (2006) Intracoronary 
Bone Marrow?Derived Progenitor Cells in Acute Myocardial Infarction. The New England 
Journal of Medicine, 355: 1210-1221.   
 
Schwarting S, Litwak S, Hao W, Bähr M, Weise J, Neumann H (2008) Hematopoietic Stem 
Cells Reduce Postischemic Inflammation and Ameliorate Ischemic Brain Injury. Stroke, 39: 
2867-2875.   
 
Seguev H, Fishman B, Ziskind A, Shulman M, Itskovitz-Eldor J (2004) Differentiation of human 
stem cells into insulin-producing cell clusters. Stem Cells, 22: 265-274. 
 
Siminiak T, Kalawski R, Fisze?????????????????????????????????????????????????????????  
(2004) Autologous skeletal myoblast transplantation for the treatment of post-infarction 
myocardial injury: Phase I clinical study with 12 months of follow-up.  American Heart Journal, 
148: 531-537.   
 
Soria B, Roche E, Berna G, Leon-Quinto T, Reig JA, Martin F (2000) Insulin-secreting cells 
derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. 
Diabetes, 49: 157-162. 
 
Spangrude GJ, Heimfeld S, Weissman IL (1988) Purification and characterization of mouse 
hematopoietic stem cells. Science, 241: 58-62. 
 
Thomas ED, Lochte HL, Lu WC, et al. (1957) Intravenous infusion of bone marrow in patients 
receiving radiation and chemotherapy.  New England Journal of Medicine, 257: 496-496.   
 
 33 
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM 
(1998) Embryonic Stem Cell Lines Derived From Human Blastocysts.  Science, 282: 1145-1147. 
 
Viacord (2011) www.viacord.com 
Victims of stroke could be helped by babies. The Times. 20 February 2001. Retrieved from: 
http://www.spuc.org.uk/about/no-less-human/ethicalstemcells.pdf 
 
Weissman I, Domen J, and Wagers A (2001) Bone Marrow (Hematopoietic) Stem Cells.  
Retrieved from: http://stemcells.nih.gov/staticresources/info/scireport/PDFs/D.%20Chapter%202.pdf 
 
Yu J, Thomson JA (2006) Embryonic Stem Cells.  NIH Publication. Bethesda, MD: 
http://stemcells.nih.gov/staticresources/info/scireport/PDFs/Regenerative_Medicine_2006.pdf 
 
 
 34 
Chapter-3:  Stem Cell E thics 
Ali Algarni 
 
In the past 14 years, following the 1998 initial isolation of human embryonic stem (ES) 
cells (Thompson et al., 1998), stem cells have been a very hot topic. The subject has attracted 
much attention due to the ability of stem cells to save lives, and medical researchers have been 
amazed at their ability to treat various diseases in animal models and in patients (discussed in 
Chapter-2).  But at the same time, many have not approved of this research, because isolating ES 
cells destroys a human embryo.  These individuals believe the costs of stem cell research 
outweigh the medical benefits to society.  The purpose of this chapter is to discuss the topic of 
stem cell ethics, paying special attention to the views of the five major world religions. 
 
The Stem Cell Debate 
One type of stem cell in particular has angered many due to the way in which these cells 
must be obtained.  ES cells require the destruction of a blastocyst prepared by in vitro 
fertilization (IVF).  Donor egg and sperm are united in a test tube, and the fertilized zygote is 
grown about 5 days to the 100-cell stage of the blastocyst.  ES cells are found in the inner cell 
mass of the blastocyst, and isolating them destroys the blastocyst.  So, the debate focuses on the 
status of the IVF human embryo.  If you argue that life begins at conception, destroying a 5-day 
old embryo is murder.  If you argue that life begins a 40-days, or even later at birth, you have 
few problems with using a 5-day old embryo to try to save lives.  The debate compares the 
benefits to society (discussed in chapter-2) with the destruction of an embryo.  Have stem cells 
benefited the medical field enough to receive the attention they are getting?  And should the 
destruction of an embryo outside the womb for the sake of saving lives be considered murder?  
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Surprising to many is the fact that the five major world religions support the use of adult 
stem cells. These cells are isolated from adult tissues (or from umbilical cord blood), and do not 
destroy an embryo.  So when some members of a particular religion argue against the use of stem 
cells, it is important to note which type of stem cell they are against.  
 
Catholics and Stem Cells 
The Roman Catholic view on stem cell research is one that is very well known.  Several 
Popes have been quoted specifically saying they are against embryo research (Pope John Paul, 
2001; American Catholic Organization, 2006).  Roman Catholics follow not only the Bible, but 
also the Pope (the Vatican).  The Catholic Church is against embryo research because Catholics 
believe life begins at conception.  So destroying a 5-day old blastocyst is murder.  Pope John 
Paul II said ES cell research is related to abortion, euthanasia, and other attacks on innocent life 
???????????????? 
 
Non-Catholic Christians and Stem Cells 
Non-Catholic Christians have a somewhat similar view on the subject as Catholics. They 
???????????????????????????????????????????????????????????????w the human embryo as a human 
life.  Christians find the creation of human life for the sake of research to be morally unethical, 
and the destruction of the blastocyst as the killing of an innocent life (Pence, 2009). Although 
some Christians are still against ES cell research, many, in fact, favor of the idea. A 2010 poll by 
the Harris Poll Company showed that only 12 percent of U.S. citizens are against stem 
biomedical research (Gardner, 2010), a very close tie to the statistic of a similar poll the 
company conducted in 2005.  In addition, Humphrey Taylor, Chairman of the Harris Poll, stated 
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that, "Even among Catholics and born-again Christians, relatively few people believe that stem 
cell research should be forbidden because it is unethical or immoral" (Gardner, 2010). 
 
Islam and Stem Cells 
Many people view Islam as being a very conservative religion. However, Islam takes a 
different approach to the subject of stem cell research than Christians.  Saudi Arabia and Iran are 
two countries that practice two different forms of Islam to the fullest, and yet they are two of the 
leading Middle Eastern countries in stem cell research. This can be a surprise to many, but unlike 
Christianity, Islam does not look at life beginning at conception, but rather at a later stage in the 
development of the embryo (Kutty and Siddiqi, 2007).  In Islam, life begins after forty days, and 
???????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????? the soul enters the body around the 40th day. 
Therefore it is not against Islamic belief or ethics to use a 5-day old embryo for research.  This 
fact is supported by the authority of Abu Abdul Rahman Abdullah ibn Masood (may Allah be 
pleased with him) who said: 
????? ????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????? ?????????????????????????
days in the form of a drop of fluid. Then it is a clinging object for a similar 
[period]. Thereafter it is a lump looking it has been chewed for a similar [period]. 
The angel is then sent to him and he breathes into him the spirit. Recorded by Al-
Bukhari and Muslim. (Az-Zarabozo, 2010). 
 
But unlike Catholics who have one authority, Islam does not have one authority to speak 
for them or to consult. Most Muslim countries have not yet introduced laws on stem cells.  
Many Muslims favor ES cell research (Ahmed, 2001), but other Muslims argue that it is 
unethical to destroy the embryos, even though they believe in that it does not have soul until later 
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stages.  But these latter individuals may fear that the technology could be used to increase the 
supply of embryos (Stem Cell Debate, 2009).  
 
Judaism and Stem Cells 
            Jewish views according to Rabbi Levi Yitschah Halpevin of the Institute for Science and 
?????????????????????????????????????????????????????????????????????????????????????????????????
frozen fertilized egg, it does not have the status of an embryo at all and there is no prohibition to 
?????????? ??????????????????????????2011). ??????????????????????????????????????????????????????
like saving lives, there is no ethical problem due to its noble cause.  Saving lives is a strong 
tradition in the Jewish faith, so all major Jewish denominations, from Reform, Conservative, 
Orthodox and Reconstructionist, are big supporters of ES and adult stem cell research, if pursued 
for medical purposes (Pew Forum, 2008).  
 
Buddhists and Stem Cells 
Buddhist teachings tend not to discuss the stem cell issue directly, but there are two main 
tenants of thought that factor into their discussion: 1) the prohibition against harming or 
destroying others (ahimsa), and 2) the pursuit of knowledge (prajma) and compassion (karma). 
These two tenants have divided Buddhist scholars and community into two main groups (Keown, 
2004). One group argues that it should be ethical to work with embryos due to its fulfilling the 
tenant about seeking knowledge and ending suffering, while the other group argues that it causes 
harm to others so it goes against tenant-1. Although Buddhists do not have a central authority, 
most seem to argue that research involving intentionally destroying an embryo is unethical 
because it goes against their belief of life beginning at conception (Keown, 2004).  
 38 
 
Hindus and Stem Cells 
Hindus also believe that life begins at conception, and like Buddhists do not have a single 
official position on the subject of stem cell research. Yet Hindus do not support abortions 
(Manickavel, 2004). Most importantly, Hindus believe in reincarnation, that the cycle of life 
??????????????? ???????????????????????????????????????????????????????????????????????????????
potential reincarnation (Bhanot, 2008).   So, overall Hindus do not support destroying an 
embryo. 
          Overall, the large religions typically have multiple stances on stem cells.  For Islam, even 
?????????????????????????????????????????????????????????????????????????????????????th day, some 
Muslims are still against ES cell research. And although the official Catholic stance is against 
destroying an embryo, some Catholics are in favor of the research.  Buddhists have the internal 
conflict of rewarding the pursuit of knowledge on one hand, while not harming life on the other 
hand.   
 
iPS Cell E thics 
Embryonic stem cells are of strong medical interest because they are pluripotent and can 
produce any cell in the adult body.  But as discussed above, they destroy an embryo to obtain 
them.  So, scientists have sought alternatives for producing pluripotent cells without destroying 
embryos.  In 2007, scientists finally achieved this with human induced pluripotent stem (iPS) 
cells (Takahashi et al., 2007).  As discussed in Chapter-2, iPS cells are skin fibroblast cells 
reprogrammed to become pluripotent by introducing the genes encoding two to four transcription 
factors that help reprogram the cells.  Because the iPS cells would be genetically compatible to 
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the patient providing the skin cell, these cells may be less likely to be rejected by the patient.  So 
hopefully these cells will not face the same ethical problems that ES cells face, while having the 
same ability to save lives. 
Although this sounds promising, iPS cells have some flaws, and may not be truly 
pluripotent.  Some scientists have reported that iPS cells grow more slowly than ES cells and 
may not be as potent (Hayden, 2011).  Other scientists have reported that iPS cells have DNA 
mutations relative to their skin fibroblast cell counterparts (Gore et al., 2011). After 
reprogramming, some iPS cell lines had a large scale genomic rearrangements and abnormal 
karyotypes, which can hinder nuclear reprogramming. Twenty two iPS cell lines were examined 
after reprogramming, and each was found to contain point mutations relative to the parental cells 
(Chol??????????????????????? ????????????????????????????????????? ?????????????????-
synonymous, nonsense, or splice variants, and were enriched in genes mutated or having 
causative effects in cancers. About half of the mutations also existed in the parental fibroblast 
progenitors at low frequencies, so the rest happened during or after the reprogramming. This 
shows that iPS cells can acquire genetic and epigenetic modifications, so such cells should be 
screened prior to therapy. 
Although the some initial studies indicated the iPS cells could form tumors at the 
injection site, later studies have omitted the c-myc transcription factor during the reprogramming 
and have not observed tumor formation (Kim et al., 2008).   
So, overall more research needs to be done with iPS cells prior to using them for therapy. 
Stem cell scientist Robert Lanza, chief scientific officer at Advanced Cell Technology in 
Worcester, Massachusetts stated, "You hear all this dialogue in the media and scientific 
community about how iPS cells are the same as embryonic stem cells, how they can solve the 
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whole controversy by removing the need for embryos. But they still can be used to satisfy 
??????????????????????????????????????????????????????????????????????????? 
 
Chapter-3 Conclusions 
?????????????????????????????????????????????????????????????????????????????????????
embryonic stem cells. They have the highest medical potential.  Their ability to differentiate into 
any type of cell in the adult organism, makes them very useful for therapeutic purposes. With an 
?????????????????? ????????????????????????????????????????????????????????????????????????????????
used after forty days.  And like many Muslim officials, I believe their usage should not be 
abused, and they should only be used to save lives.  With respect to the source of the embryo 
used to derive ES cells, I believe that scientists should use discarded reproductive IVF embryos 
only after the couples have declared that they have no further need for them.  And I believe that 
embryos created for the purpose of research by IVF or cloning are a valid source for research, 
providing the egg and sperm donors have informed consent.  I see no problem with providing 
money to the donors, so long as it is done with tight regulation to prevent someone from making 
a living doing it.  
The use of adult stem cells is a great achievement. Although they are not as potent as ES 
cells, their potential may be higher than originally thought.  Scientists showed in 2006 that 
hematopoietic stem cells can form blood vessels in addition to blood cells (Adult Stem 
??????????????????????????????????????????????????I still believe that ES cells are much more 
promising and should receive the most attention.   I am also in favor of using iPS cells, although 
I do not believe they are as potent as ES cells, and should not detract from ES cell research.  
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Chapter-4: Stem Cell Legalities 
Abdulla Al-Abri 
 
 Controversial scientific technologies need laws governing their use.  As discussed in 
previous chapters, the topic of stem cells is one of the most hotly debated topics in bio-ethics 
today.  This topic is an interesting and frustrating blend of science, politics, and money.  In this 
chapter, the laws that govern stem cell use will be discussed.  Understanding the various actions 
taken in the U.S. and abroad to regulate stem cell research may help the reader develop his own 
stand on stem cells.  As discussed in previous chapters, the stem cell debate focuses on the status 
of the human embryo.  The wide diversity of views on the use of embryos and stem cell research 
originates from widely diverse religious and cultural stances, and this creates a strong debate in 
society. The U.S. federal and state policies on embryo research will be discussed from the 
Clinton administration to the present Obama administration, along with the policies of several 
other countries. 
 
Main Legal Issues with Stem Cells 
 As discussed in previous chapters, the main stem cell controversy focuses on the status of 
a 5-day old human embryo used to derive embryonic stem (ES) cells.  The embryo is created by 
uniting sperm and egg in vitro, and growing 5 days to the blastocyst stage from which the ES 
cells are isolated.  The ethical debate (and subsequent laws) focuses on whether the destruction 
of this 5-day old embryo is murder, and if so, it is banned by that administration from receiving 
federal money to support the research.  Individual states can also fund the research on their own, 
as occurred during the federal ban by the Bush administration, and we will discuss the leadership 
roles of California, New Jersey, and Massachusetts in this role.   
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 The embryo debate by U.S. presidents and by congress is not new.  It began in the late 
???????????????????????????????????????????????????irst test tube baby (BBC News, 1978).  These 
test tube embryos are created at fertility clinics, and are created in excess as it is impossible to 
know in advance how many tries will be needed to achieve a pregnancy.  The debate focuses on 
what to do with the excess embryos once the couple has enough children.  Governments have 
enacted policies since these embryos began being used for research purposes.   
  
The United States Federal Laws on Embryos 
The United States has always been active at governing science and technology.  The U.S. 
has not been mute in the embryo debate, but been very responsive on this issue, changing stances 
from being highly restrictive to being somewhat permissive with strong oversight.  
 
Clinton Administration: Very Pro-Stem Cells  
President Clinton was generally in favor of using federal money to pay for embryo and 
????? ????? ?????????? ? ??? ??????? ????? ????????? ?????? ?????????? ????? ??????? ???? ????????? ?????????
children and hoping that stem cells might cure them (Clinton, 2004).  The American Diabetes 
Association called the use of stem cells to produce insulin the most important advancement in 
diabetes research since the development of insulin (American Diabetes Association, 2012).  In 
December 1994, to begin a debate about embryo usage, President Clinton directed the National 
Institutes of Health (NIH) to temporarily abstain from providing any resources to support the 
creation of human embryos for research purposes, and established a National Bioethics Advisory 
Commission to consider the complex topic (Clinton, 1994). After a year, the advisory 
commission recommended using surplus IVF embryos for research purposes.   
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However, before much embryo research could be funded, in 1995 congress passed the 
Dickey-Wicker Amendment that prohibited the Department of Health and Human Services 
?????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????
Stem Cell Laws, 2005). This law was described under 45 CFR 46.204 and 46.207, and 
subsection 498(b) of the Public Health Service Act (Genetics and Public Policy Center, 2011). 
The restriction of federal money for embryo research caused an increase in private 
funding.  By 1998, the volume of research being conducted using embryos increased, and in this 
same year James Thomson and co-workers at the University of Wisconsin in a private institute 
became the first scientists to derive and successfully culture human ES cells from a blastocyst 
(Thomson et al., 1998).  Prior to this achievement, ES cells had been derived from mouse 
blastocysts in 1981 (Martin, 1981; Guidelines for hES Cell Research, 2005).  In August of 2000, 
the NIH released new guidelines for allowing federal funding of ES cell research (NIH, 2000) 
and President Clinton supported their recommendations. But before any applications were 
reviewed or money allocated, President Bush came into office (Kruse, 2009). 
In general, although the Clinton administration was in favor of stem cells, for much of his 
term of office congress acting on public concerns over-rode him.  But under his watch, human 
ES cells were discovered, and embryo research had its first success under private funding.  
 
Bush Administration: Anti-Embryonic Stem Cells 
President George Bush was inaugurated in January of 2001.  Although more than 50% of 
Americans (regardless of race or religious affiliation) supported stem cell research and believed 
it should be funded by the federal government, Bush made his mark on the topic by announcing 
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in August 2001 that federal funding would not be allowed to derive any new ES cell lines (hES 
????? ?????????????? ????? ??? ???? ??????????? ???????? ???? ?????????? ?????? ??? ????? ??? ???? ???
August 9, 2001, and with donor consent, could the ES cell line be used, as those embryos had 
already been destroyed (Bush, 2001).  As a result of this 2001 policy, only 60 hES cell lines were 
initially available for federal support, and many of these cell lines later turned out to be damaged 
or aged, making far fewer available lines (Holden and Vogel, 2002).  Many in the scientific 
community worried this lack of ES cell lines would severely hinder the U.S. leadership position 
in this field (Rowley et al., 2002; Cook, 2004; Ford, 2006).  The NIH monitored several stem cell 
researchers from India, Israel, Singapore, Sweden, and South Korea that became federally 
???????? ??? ?????? ????????????????????????????????? ????????? ?????????? ???????? ??????? ?????????
Embryonic Stem Cell Registry was created to list the human ES cell lines that met the eligibility 
criteria (NIH.gov, 2006). 
????????? ????????????????????????????????????????????????????????? ??????????????????????
??????????????????? ??? ?????? ???? ???????? ???????????? ???????????? ?? ???? ??? reproductive 
cloning and a four-year moratorium on therapeutic cloning for medical research purposes.  The 
National Academy of Science recommended that human reproductive cloning should not be 
practiced because it is dangerous and most likely would fail, but it recommended that therapeutic 
cloning to produce patient-specific stem cells should be permitted because of the potential for 
developing new therapies and advancing biomedical knowledge (Genetics and Public Policy 
Center, 2011).  But in spite of these recommendations, the 2001 ban on federal funding for ES 
cell research prevailed. 
Under the Bush administration, the conduct of research on human ES stem cells remained 
tightly regulated.  Due to an increase in public support for ES cell research (Langer, 2005), 
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congress twice voted to approve such research, and twice President Bush vetoed the bills.  
President Bush used his veto power for the first time as he stated that an embryonic stem-cell 
?????????????????????????????????????????????????????????????????? ???????????????????????? to 
stop a legislation intended to ease the restrictions he originally imposed on stem cell research in.  
?????????????????????????????????????????????????????????????????????????????????????????????????
to promote science which destroys life in order to save life (Baker, 2005).  He stated that the 
??????? ????? ??????? ???????? ???? ??????? ??? ????????? ?????? ????? ??? ???? ????? ??? ????????????????
????????? ?????????????????? ???????????????????????????????????????????? ?????? ?????? ????????????
embryos, he emphasized that these boys and girls are not spare parts. Bush said that if the bill 
were to become a law, American taxpayers would for the first time in the U.S. history be 
compelled to fund the deliberate destruction of human embryos (Babington, 2006).  As expected, 
many questioned the decisions made by Bush regarding stem cell research, but Bush was firm 
with his decisions.  In 2004, he even replaced two advocates of stem cell research on his 
bioethics council with three people who are less approving of stem cell research (Stem Cell 
Laws, 2005). 
In general, the Bush administration was anti-ES stem cell research, in spite of rising 
public support for it. In 2007, a national poll indicated that a slim majority of  
Americans supported the research, and the Pew Forum on Religion and Public Life and the Pew 
Research Center for the People & the Press found that only 35% of individuals declare it is more 
important not to destroy embryos than to use them to save lives (Vestal, 2008).  Because of the 
Bush policy on federal restrictions, scientists looked abroad for collaborators who had access to 
more ES cell lines (Cook, 2004), and others argued that a lack of support for stem cell research 
in the US resulted in the country falling behind other nations in this area (Ford, 2006).  In 
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addition, during the Bush administration, several key states took it into their own hands to use 
state money to fund their own stem cell initiatives, discussed below. 
 
Obama Administration: Pro-Stem Cells  
President Obama promised during his presidential campaign that he would overturn 
restrictions on the federal funding of ES cell research (Langer, 2009).  Soon after his 
inauguration, on March 9, 2009, Obama signed an executive order ending an 8-½ -year ban on 
federal funding for ES cell research. This ?????????????????????????????????????????????? ???
?????????????????????????????????????????????????????????????????????????????????????????????
He expressed his vigorous support to scientists who pursue stem cell research, and aimed for 
America to lead the world in the discoveries it one day may yield.  With this order, scientists and 
researchers can currently use federally funded equipment in their main laboratory and new 
federal dollars to do ES cell research.  Scientists and research advocates worldwide celebrated 
this over-turn of the 2001 ban (Hayden, 2009).  He also lifted the prohibition on U.S. funding for 
international groups that promote this research, and proposed rescinding job protections for 
health-care workers who decline to carry out procedures that conflict with their moral beliefs 
????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????? 
The National Institutes of Health was given 120 days to develop ethical guidelines for the 
research (Childs and Stark, 2009), and the guidelines underwent several revisions. But in the end, 
spare IVF embryos were allowed for ES cell research, if the sperm and egg donors had provided 
consent.  But embryos ????????????? ???????? ??????? ???? ??????????????????? ????? ????????????????
order did not open the door to human reproductive cloning, which was clearly banned.  He 
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reiterated that there would be strict guidelines not to tolerate misuse or abuse of embryos.  He 
further emphasized that human reproductive cloning is dangerous, profoundly wrong, and has no 
place in society (CBS, 2009). 
In 2009, President Obama also signed a memorandum that restores scientific integrity in 
government decision-making. The memorandum covers all scientific research, and help ensures 
that public policy is guided by sound scientific advice (Borenstein and Feller, 2009; Childs and 
????????????????????????????????????????????????????????????????????????????????????????????????????
about pr????????? ????? ???? ????? ????????? ?????? ??????? ?????????? ?????? ?????????? ????? ????
????????????????????????????????????????????????? ????????????????????????? ???? ?????????????????
generated on both sides of the long, contentious debate (CBS/The Associated Press, 2009).   
??? ????????? ??????????? ???? ?????? ????? ???????? ????? ????? ??????? ????????? ??????? ????
because the executive order still mandated that the embryos come from reproductive clinics, and 
not be created solely for research, some scientists complained that the new policy remains too 
restrictive.  The NIH Guidelines on human stem cell research established the policies and 
procedures under which the NIH will be allowed to fund such research.  The guidelines were put 
into effect to ensure that NIH-funded research in this area is ethically responsible, scientifically 
worthy, and conducted in accordance with applicable laws.  The final guidelines were placed into 
effect on July 7, 2009 (Holden, 2009), and adhered to the well-established norms for informed 
donor consent.  The rigorous NIH guidelines have already been used to ban dozens of ES cell 
?????????????????????????????????????????????????????????????????????????????????? ??????????????????
?????????????????????????????????????? 
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U .S. State Policies on Embryos and Stem Cell Research 
 During the Bush administration ban on federal funding to derive new ES cell lines, 
several states took the initiative to fund the research on their own.  Several key states, such as 
New Jersey, California, and Massachusetts led the way to fund their own stem cell initiatives and 
institutes. 
New Jersey.  On June 25, 2004, the New Jersey legislators passed a state budget that 
included $9.5 million for a newly chartered Stem Cell Institute of New Jersey (Palca, 2007).  
This move made New Jersey the first state to fund research on stem cells including those derived 
????? ?????? ????????? ? ??? ????????? ???? ?????? ???? ???????? ??????????? ??? ???????? ????
Technology awarded $5 million to research teams throughout the New Jersey (The Commission 
on Science and Technology, 2007).  
 California.  ???????????????????????????????????????????????????????????????? became the 
second state to fund ES cell research.  On November 2, 2004 California voters approved 
Governor Schwarzenegger provision of $3 billion to support stem cell research over a decade 
and to establish the California Institute for Regenerative Medicine (CIRM) (Palca, 2007). In 
2011, the governing board of CIRM approved $30 million toward a program that will cultivate 
partnerships between stem cell scientists and biotech and pharmaceutical companies.  CIRM also 
approved a separate future $38 million to foster scientific innovation in high school students, and 
to fund basic stem cell discoveries (GEN, 2011). 
 Connecticut.  On May 31, 2005 Connecticut allocated $100 million annual funding to 
fund stem cell therapies for a wide range of diseases, and to be one of the premier stem-cell 
research centers over the next 10 years.  One month later, on June 15, 2005 Governor Jodi Rell 
signed a public act that permits stem cell research and bans human cloning (Associated Press, 
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2005).  The act appropriates $20 million for conducting embryonic or human adult stem cell 
research (Palca, 2007). 
 I llinois.  On July 13, 2005, the Illinois state legislature created a stem-cell research 
institute by executive order.  The Public Health Department was given $10 million to fund 
research (Palca, 2007).   
 Massachusetts. On June 1, 2005, Massachusetts state legislators overturned Governor 
????????????????????????????????ing stem cell research (Massachusetts Stem-Cell Bill Becomes 
Law Despite Veto, 2005). The legislation created an Institute for Stem Cell Research and 
Regenerative Medicine at the University of Massachusetts Medical School with an appropriation 
of $1 billion dollars to be spent on the stem cell biology core. It also established the 
Massachusetts Life Sciences Center (MLSC) to promote life science research in the advanced 
and applied sciences, and includes regenerative medicine, biotechnology, and nanotechnology 
(Embryonic and Fetal Research Laws, 2008). With the sufficient funds allocated, the 
Massachusetts hESC Bank and Registry was designed to serve as an international repository of 
human embryonic stem cells derived in Massachusetts and beyond (Shelton, 2007). 
 
 General States and Stem Cells:  As of January 2008, the states of California, 
Connecticut, Illinois, Indiana, Iowa, Maryland, Massachusetts, and New York permitted ES cell 
research under certain conditions (State Embryonic & Fetal Research Laws as of January, 2008).  
But other states have enacted laws banning ES cell research, while other states have no stem cell 
policies at all. For those states that allow ES cell research, the conduct of such research is still 
governed by strict guidelines to ensure safety and health purposes, and to avoid misuse and abuse 
of the use of human embryos.   
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Other Countries and Stem Cells 
 Other countries beside the United States have also welcomed the idea of supporting stem 
cell research.  Research has shown that stem cell research is strongly affected by federal policies 
in the USA, Japan, Germany, the UK and France (Couffignal-Szymzcak, 2009).  These countries 
were also the top five countries publishing stem cell articles. 
 On June 6, 2001, Japan banned reproductive cloning through its law on Human Cloning 
Techniques and other Similar Techniques.  But in general, Japan is favorable to ES cell research.  
??????????????????????????????????????????????????????????????????????????????????????????????
of its Bioethics Expert Panel on human embryo and stem cell research.  The report recommended 
allowing the creation of human embryos for stem cell research (Couffignal-Szymzcak, 2009).   
 The 25 member states of Europe took very different regulatory positions on human 
embryonic stem cell research, reflecting the diversity of ethical, philosophical, and religious 
beliefs throughout Europe. UK and Belgium have similar legal positions that allow the 
procurement of human ES cells from surplus IVF embryos, and the creation of human embryos 
for research.  However, Germany and Italy prohibit the procurement of human ES cells from 
human embryos, while Austria, Bulgaria, Cyprus, Ireland, Lithuania, Luxembourg, Malta, 
Poland, Romania, and Slovakia have no specific legislation at all in this area (What 
????????????? ????????? ???????????? ???? ????????????????????? ?????????? ??? ??????? ???????????
that would make European money available for stem cell research (Deutsche, 2006).   
 On May 1, 2009, China introduced new regulations on the clinical use of stem cells.  The 
regulations promote the development of medical science and technology that improve the quality 
and safety stem cell care. Under this law, medical technology should follow standardized 
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scientific and ethical principles for providing safe, effective care (Stem Cell Transplantation 
Department, 2011). 
 Other countries have also explored stem cell research, such as Iran, Norway, South 
Africa, and South Korea.  In Iran, stem cell research got both religious and political backing, so 
Iran is quite liberal regarding stem cell research.  In South Korea, biotechnology is an important 
industry, and stem cell research is one of the government priorities receiving large funding.  
South Africa allows creating human embryos solely for research.  The Research Council of 
Norway granted 170 million Norwegian kroner to support stem cell research in 2002-2013 (Erik, 
2011). 
  
Chapter-4 Conclusions 
 Since the advent of test tube babies in 1978, countries have debated what to do with the 
surplus IVF embryos.  The embryo debate escalated considerably following the 1998 isolation of 
human ES cells from embryos, and their potential to treat a wide variety of diseases.  In the U.S., 
embryo policies have strongly reflected the particular administration in office, from Clinton to 
Bush to Obama.  What makes the issue complicated, and what calls for specific laws and policies 
?????? ????????????????????????? ???? ????????????????????????? ???? ??????????????????? ????? ???? ????
status of a 5-day old embryo.  People are confronted with the dilemma of whether destroying a 5-
day old IVF embryo is murder, versus potentially saving existing lives.  Debates have pressured 
each administration, state, and many countries to pass their own laws on this topic.  What can be 
recognized by the research performed in this chapter is the effort made by a variety of entities to 
understand the science, and create guidelines to prevent the misuse of the embryo and the stem 
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cells.  All countries appear to ban reproductive cloning, but only some countries have bothered to 
pass the appropriate legislation on this topic.   
 Regardless of the debates, laws and guidelines, the world does not hold a singular 
position on ES cell research. Human ES cells are still perceived to be the best material for tissue 
regeneration.  As this research continues, and new findings become apparent, new laws will need 
to be enacted.  May stem cell researchers never forget that they too come from embryos, and use 
such embryos cautiously for saving lives. 
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PR OJE C T C O N C L USI O NS 
 
 
 
 The potential of stem cells to enhance man???????health and prolong life, regardless of 
the source of the stem cell, is undeniably commendable.  The controversies, ethical and legal, are 
all valued and should be carefully weighed, so each of us must develop our own conviction about 
stem cell research but in consonance with what could be better for all.  After gaining 
fundamental knowledge about stem cells, the authors now make their own conclusions on the 
subject.  The authors support the use of all types of stem cells, but do not support the creation of 
embryos solely for research purposes.  As to the source of embryos used to derive the ES cells, 
the authors support the use of surplus IVF embryos, so long as the donors provided consent that 
they be used for research.  But the authors disagree with each other on whether donors should be 
allowed to receive monetary compensation; author Ali sees no harm with allocating money to 
egg or sperm donors, so long as they provide informed consent to use the material for research.  
On the other hand, author Abdulla argues that providing money to donors could push individuals 
into performing risky egg donation procedures solely because they are poor, and such an act 
lessens the value of human life and the essence of reproduction. 
Given that all ES cell lines are derived from embryos regardless of how the embryo is 
created, whenever possible, the authors agree with attempting to use adult stem cells or induced 
pluripotent stem (iPS) cells instead of ES cells for treating a specific disease. Who knows, 
perhaps one of the embryos being destroyed has the potential to be a great scientist someday.   
 With respect to stem cell legislation, the authors most agree with current U.S. laws under 
the Obama administration.  Obama?s 2009 overturning of Bu???????????????????(that restricted 
federal funding for ES cell research) now allow new ES cell lines to be derived from embryos 
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but with some restrictions, including being surplus IVF embryos created for reproductive 
purposes, and the donors must provide their consent that the embryos can be used for research.  
These policies help show that the government is mindful of the values of human life and the 
essence of reproduction.  Both authors strongly favor allowing federal and state funding for 
human stem cell research, and especially appreciate the current NIH ethical guidelines that bans 
creating embryos solely for research purposes, and bans reproductive cloning.  The current 
Obama policies that exist in the United States are indeed logical and ethical. 
 Stem cell technology is one of the hottest debates in all of politics and science today, and 
will continue to be for years to come.  The search for safe life-saving applications continues, and 
so does the challenge for all of us to keep up with this progress without sacrificing the values of 
human life.  
 
